We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Tamiflu Confirmed Effective for Avian Flu

By HospiMedica staff writers
Posted on 01 Aug 2005
A new study in mice has confirmed that Tamiflu (oseltamivir), used against influenza strains, is effective against the avian flu virus H5N1.

The study was conducted by researchers at St. More...
Jude Children's Hospital (Memphis, TN, USA) who used oseltamivir to treat mice infected with the H5N1 virus. The highest dose used was equivalent to the dose currently recommended for humans sick with the flu. Of 80 mice infected with the virus, 20 received a placebo, 30 were given oseltamivir at one of three dosage levels for five days, and 30 received the drug at one of three dosage levels for eight days. None of the mice receiving placebo survived. Only five of the 10 mice given the highest daily dose for five days survived. Although oseltamivir suppressed the virus in the mice, the virus continued to grow if the drug was stopped after five days.

Mice given the drug for eight days, on the other hand, fared better. Survivors included one of 10 mice given the lowest daily dose, 2 of 10 given the middle-range daily dose, and eight of 10 given the highest daily dose. Oseltamivir decreases the ability of the influenza virus to spread from infected cells to uninfected cells by inhibiting neuraminidase, a protein required for the virus to exit infected cells.

Public health experts fear that this avian flu strain could develop the ability to easily spread from person to person and kill millions in a pandemic. "The H5N1 avian flu viruses are in a process of rapid evolution,” noted Elena A. Goborkova, Ph.D., of St. Jude Children's Hospital. "Our results provide baseline information that will be needed for further studies on preventing and treating avian flu with antiviral drugs.

The St. Jude researchers say further study is needed to see if using higher doses of oseltamivir for a longer period of time can prevent the H5N1 virus in the lungs from gaining a foothold and then spreading to the brain.




Related Links:
St. Jude Children's Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.